E

Promising new combos in cancer research pipelines

Four more combination trials of interest in cancer research that may be worth watching out for

November 2, 2016
E

ESMO16 Gems from the Poster Halls Part 2

Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...

November 1, 2016
E

Insights from biomarkers in ovarian cancer

Can biomarkers help us improve clinical trial outcomes?

October 25, 2016
E

Where does rucaparib fit in ovarian cancer?

How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?

October 24, 2016
E

What do Myriad Genetics really think of the Niraparib data?

Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented

October 20, 2016
E

New Directions in Advanced Lung Cancer

Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…

October 19, 2016
E

ESMO16 Day 3 Daily Digest

Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium

October 10, 2016
E

ESMO16 Day 2 Digest

Commentary on Day 2 at ESMO16

October 8, 2016
E

What Tesaro aren’t telling you about niraparib

What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.

October 8, 2016
E

ESMO16 Congress Day 1 Digest

Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.

October 7, 2016
E

ESMO16 Preview 7 Key Trials in Breast Cancer

A look at some of the key breast cancer abstracts to watch out for at #ESMO16 in Copenhagen

September 14, 2016
E

ESMO16 Preview Novel Targeted Therapies

Five key approaches in developmental therapeutics in the spotlight at ESMO16

September 13, 2016
E

What’s Hot in Ovarian Cancer at ESMO16?

A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect

September 8, 2016
E

ESMO16 What’s Hot in Head and Neck Cancer?

What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?

September 7, 2016
E

ESMO16 Preview on Late Breaking Abstracts in Lung Cancer

A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?

September 6, 2016
E

ESMO16 Preview 1 Novel Target Data Offers Potential to Overcome Barriers to Cancer Drug Resistance

Overcoming barriers to resistance in epithelial cancers - a look at a novel oncogenic target

September 1, 2016